Trinity Biotech (TRIB) versus The Competition Critical Analysis
Trinity Biotech is one of 24 publicly-traded companies in the "Diagnostic substances" industry, but how does it contrast to its rivals? We will compare Trinity Biotech to related businesses based on the strength of its risk, dividends, analyst recommendations, profitability, valuation, earnings and institutional ownership. Trinity Biotech has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.
from Biotech News
0 Comments